ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 280,24
-0,08%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immuneering Corporation (IMRX)

  7. Immuneering Corporation (IMRX) Actualités

IMRX

Immuneering (IMRX)

Immuneering Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:IMRX
DateHeureSourceTitreSymboleSociété
29/05/202422h05GlobeNewswire Inc.Immuneering to Present at the Jefferies Global Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
23/05/202422h20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMRXImmuneering Corporation
23/05/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMRXImmuneering Corporation
07/05/202422h05GlobeNewswire Inc.Immuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
06/05/202422h30GlobeNewswire Inc.Immuneering Recognizes Melanoma Awareness MonthNASDAQ:IMRXImmuneering Corporation
09/04/202418h00GlobeNewswire Inc.IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsNASDAQ:IMRXImmuneering Corporation
03/04/202422h05GlobeNewswire Inc.Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
27/03/202413h00GlobeNewswire Inc.Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
14/03/202412h00GlobeNewswire Inc.Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
12/03/202413h00GlobeNewswire Inc.Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of DirectorsNASDAQ:IMRXImmuneering Corporation
11/03/202413h00GlobeNewswire Inc.Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid TumorsNASDAQ:IMRXImmuneering Corporation
05/03/202423h00GlobeNewswire Inc.Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024NASDAQ:IMRXImmuneering Corporation
04/03/202414h00GlobeNewswire Inc.Immuneering to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:IMRXImmuneering Corporation
01/03/202414h05Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:IMRXImmuneering Corporation
01/03/202414h00GlobeNewswire Inc.Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
20/02/202414h00GlobeNewswire Inc.Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic CancerNASDAQ:IMRXImmuneering Corporation
16/01/202422h37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IMRXImmuneering Corporation
12/12/202314h00GlobeNewswire Inc.Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS MutationsNASDAQ:IMRXImmuneering Corporation
20/11/202322h05GlobeNewswire Inc.Immuneering to Present at the 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
09/11/202322h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMRXImmuneering Corporation
09/11/202322h05GlobeNewswire Inc.Immuneering Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
12/10/202322h05GlobeNewswire Inc.Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC ConferenceNASDAQ:IMRXImmuneering Corporation
04/10/202322h05GlobeNewswire Inc.Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsNASDAQ:IMRXImmuneering Corporation
06/09/202314h00GlobeNewswire Inc.Immuneering to Present at the Morgan Stanley Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
03/08/202322h05GlobeNewswire Inc.Immuneering Reports Second Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:IMRXImmuneering Corporation
15/06/202322h40Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMRXImmuneering Corporation
15/06/202322h17Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMRXImmuneering Corporation
05/06/202314h00GlobeNewswire Inc.Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid TumorsNASDAQ:IMRXImmuneering Corporation
30/05/202314h00GlobeNewswire Inc.Immuneering to Present at the Jefferies Healthcare ConferenceNASDAQ:IMRXImmuneering Corporation
05/05/202317h54Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:IMRXImmuneering Corporation
 Showing the most relevant articles for your search:NASDAQ:IMRX

Dernières Valeurs Consultées

BIT
P1QKR0
BNP Paribas Issuance
AMEX
FLDR
Fidelity Low Duration Bo...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés